Company news
vTv Therapeutics Inc. news in 2021
vTv Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
December 5, 2021
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
November 8, 2021
vTv Therapeutics Announces Deepa Prasad as New President and CEO
October 19, 2021
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
October 11, 2021
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
September 22, 2021
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
August 3, 2021
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
June 28, 2021
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
June 21, 2021
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
May 4, 2021
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
April 12, 2021
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
April 11, 2021
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
March 22, 2021
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
March 17, 2021
vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 7, 2021
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
February 23, 2021
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
February 22, 2021
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
February 16, 2021
vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
January 5, 2021